Quantbot Technologies LP Makes New Investment in Evolent Health, Inc. (NYSE:EVH)

Quantbot Technologies LP purchased a new stake in Evolent Health, Inc. (NYSE:EVH) during the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm purchased 120,056 shares of the technology company’s stock, valued at approximately $1,351,000.

A number of other institutional investors have also made changes to their positions in EVH. Wellington Management Group LLP grew its holdings in Evolent Health by 12.8% in the 3rd quarter. Wellington Management Group LLP now owns 12,595,459 shares of the technology company’s stock valued at $356,200,000 after buying an additional 1,426,747 shares during the last quarter. Eventide Asset Management LLC grew its stake in shares of Evolent Health by 1.7% in the third quarter. Eventide Asset Management LLC now owns 3,804,104 shares of the technology company’s stock worth $107,580,000 after acquiring an additional 64,985 shares during the last quarter. State Street Corp increased its position in Evolent Health by 1.0% during the third quarter. State Street Corp now owns 2,725,375 shares of the technology company’s stock worth $77,074,000 after acquiring an additional 25,967 shares during the period. Bellevue Group AG raised its stake in Evolent Health by 59.9% during the 3rd quarter. Bellevue Group AG now owns 2,670,050 shares of the technology company’s stock valued at $75,509,000 after purchasing an additional 1,000,215 shares during the last quarter. Finally, Boston Partners boosted its holdings in Evolent Health by 92.0% in the 4th quarter. Boston Partners now owns 2,444,006 shares of the technology company’s stock valued at $27,097,000 after purchasing an additional 1,171,304 shares during the period.

Evolent Health Trading Up 1.1 %

Shares of EVH opened at $9.69 on Tuesday. The company has a debt-to-equity ratio of 0.58, a quick ratio of 1.04 and a current ratio of 1.04. The company has a market cap of $1.13 billion, a price-to-earnings ratio of -11.81 and a beta of 1.49. The stock has a fifty day moving average price of $9.88 and a two-hundred day moving average price of $15.92. Evolent Health, Inc. has a 52-week low of $8.35 and a 52-week high of $33.63.

Evolent Health (NYSE:EVH) last issued its quarterly earnings results on Thursday, February 20th. The technology company reported $0.03 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.38 by ($0.35). Evolent Health had a positive return on equity of 5.73% and a negative net margin of 2.41%. The company had revenue of $646.54 million for the quarter, compared to analyst estimates of $650.92 million. Analysts predict that Evolent Health, Inc. will post 0.08 EPS for the current fiscal year.

Insider Buying and Selling

In other Evolent Health news, President Daniel Joseph Mccarthy bought 11,040 shares of the business’s stock in a transaction on Thursday, March 6th. The shares were bought at an average cost of $9.01 per share, for a total transaction of $99,470.40. Following the transaction, the president now owns 389,004 shares in the company, valued at approximately $3,504,926.04. This trade represents a 2.92 % increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, CEO Seth Blackley purchased 55,225 shares of the stock in a transaction dated Thursday, March 6th. The shares were acquired at an average price of $9.01 per share, with a total value of $497,577.25. Following the transaction, the chief executive officer now owns 762,217 shares in the company, valued at $6,867,575.17. This trade represents a 7.81 % increase in their ownership of the stock. The disclosure for this purchase can be found here. Insiders purchased 74,000 shares of company stock worth $666,315 in the last quarter. Insiders own 1.60% of the company’s stock.

Analysts Set New Price Targets

A number of research analysts have recently commented on the stock. BTIG Research cut their price objective on shares of Evolent Health from $36.00 to $29.00 and set a “buy” rating for the company in a research report on Tuesday, December 3rd. JMP Securities reissued a “market outperform” rating and set a $12.00 price objective on shares of Evolent Health in a report on Friday, February 14th. Citigroup cut their target price on Evolent Health from $21.00 to $18.00 and set a “buy” rating for the company in a research note on Friday, January 10th. Stephens lowered their price target on shares of Evolent Health from $16.00 to $12.00 and set an “equal weight” rating on the stock in a report on Tuesday, January 21st. Finally, Canaccord Genuity Group reduced their price objective on shares of Evolent Health from $23.00 to $16.00 and set a “buy” rating for the company in a report on Thursday, January 23rd. One investment analyst has rated the stock with a hold rating, twelve have given a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Buy” and an average target price of $17.71.

Evolent Health Company Profile

Evolent Health, Inc, through its subsidiary, Evolent Health LLC, offers specialty care management services in oncology, cardiology, and musculoskeletal markets in the United States. The company provides platform for health plan administration and value-based business infrastructure. It offers administrative services, such as health plan services, pharmacy benefits management, risk management, analytics and reporting, and leadership and management; and Identifi, a proprietary technology system that aggregates and analyzes data, manages care workflows, and engages patients.